Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.

To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting patients with psoriatic arthritis (PsA). GRAPPA rheumatologists, dermatologists, and PsA patients drafted overarching principles for the management of PsA, based on consensus achieved at face-to-face meetings and via online surveys. We conducted literature reviews regarding treatment for the key domains of PsA (arthritis, spondylitis, enthesitis, dactylitis, skin disease, and nail disease) and convened a new group to identify pertinent comorbidities and their effect on treatment. Finally, we drafted treatment recommendations for each of the clinical manifestations and assessed the level of agreement for the overarching principles and treatment recommendations among GRAPPA members, using an online questionnaire. Six overarching principles had ≥80% agreement among both health care professionals (n = 135) and patient research partners (n = 10). We developed treatment recommendations and a schema incorporating these principles for arthritis, spondylitis, enthesitis, dactylitis, skin disease, nail disease, and comorbidities in the setting of PsA, using the Grading of Recommendations, Assessment, Development and Evaluation process. Agreement of >80% was reached for approval of the individual recommendations and the overall schema. We present overarching principles and updated treatment recommendations for the key manifestations of PsA, including related comorbidities, based on a literature review and consensus of GRAPPA members (rheumatologists, dermatologists, other health care providers, and patient research partners). Further updates are anticipated as the therapeutic landscape in PsA evolves.

Coates LC ，Kavanaugh A ，Mease PJ ，Soriano ER ，Laura Acosta-Felquer M ，Armstrong AW ，Bautista-Molano W ，Boehncke WH ，Campbell W ，Cauli A ，Espinoza LR ，FitzGerald O ，Gladman DD ，Gottlieb A ，Helliwell PS ，Husni ME ，Love TJ ，Lubrano E ，McHugh N ，Nash P ，Ogdie A ，Orbai AM ，Parkinson A ，O'Sullivan D ，Rosen CF ，Schwartzman S ，Siegel EL ，Toloza S ，Tuong W ，Ritchlin CT ... -  《-》

Treatment recommendations for psoriatic arthritis.

Ritchlin CT ，Kavanaugh A ，Gladman DD ，Mease PJ ，Helliwell P ，Boehncke WH ，de Vlam K ，Fiorentino D ，Fitzgerald O ，Gottlieb AB ，McHugh NJ ，Nash P ，Qureshi AA ，Soriano ER ，Taylor WJ ，Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) ... -  《-》

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF). We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of available pharmacologic and nonpharmacologic therapies for PsA. GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology was used to rate the quality of the evidence. A voting panel, including rheumatologists, dermatologists, other health professionals, and patients, achieved consensus on the direction and the strength of the recommendations. The guideline covers the management of active PsA in patients who are treatment-naive and those who continue to have active PsA despite treatment, and addresses the use of oral small molecules, tumor necrosis factor inhibitors, interleukin-12/23 inhibitors (IL-12/23i), IL-17 inhibitors, CTLA4-Ig (abatacept), and a JAK inhibitor (tofacitinib). We also developed recommendations for psoriatic spondylitis, predominant enthesitis, and treatment in the presence of concomitant inflammatory bowel disease, diabetes, or serious infections. We formulated recommendations for a treat-to-target strategy, vaccinations, and nonpharmacologic therapies. Six percent of the recommendations were strong and 94% conditional, indicating the importance of active discussion between the health care provider and the patient to choose the optimal treatment. The 2018 ACR/NPF PsA guideline serves as a tool for health care providers and patients in the selection of appropriate therapy in common clinical scenarios. Best treatment decisions consider each individual patient situation. The guideline is not meant to be proscriptive and should not be used to limit treatment options for patients with PsA.

Singh JA ，Guyatt G ，Ogdie A ，Gladman DD ，Deal C ，Deodhar A ，Dubreuil M ，Dunham J ，Husni ME ，Kenny S ，Kwan-Morley J ，Lin J ，Marchetta P ，Mease PJ ，Merola JF ，Miner J ，Ritchlin CT ，Siaton B ，Smith BJ ，Van Voorhees AS ，Jonsson AH ，Shah AA ，Sullivan N ，Turgunbaev M ，Coates LC ，Gottlieb A ，Magrey M ，Nowell WB ，Orbai AM ，Reddy SM ，Scher JU ，Siegel E ，Siegel M ，Walsh JA ，Turner AS ，Reston J ... -  《-》

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021.

Since the second version of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations were published in 2015, therapeutic options for psoriatic arthritis (PsA) have advanced considerably. This work reviews the literature since the previous recommendations (data published 2013-2020, including conference presentations between 2017 and 2020) and reports high-quality, evidence-based, domain-focused recommendations for medication selection in PsA developed by GRAPPA clinicians and patient research partners. The overarching principles for the management of adults with PsA were updated by consensus. Principles considering biosimilars and tapering of therapy were added, and the research agenda was revised. Literature searches covered treatments for the key domains of PsA: peripheral arthritis, axial disease, enthesitis, dactylitis, and skin and nail psoriasis; additional searches were performed for PsA-related conditions (uveitis and inflammatory bowel disease) and comorbidities. Individual subcommittees used a GRADE-informed approach, taking into account the quality of evidence for therapies, to generate recommendations for each of these domains, which were incorporated into an overall schema. Choice of therapy for an individual should ideally address all disease domains active in that patient, supporting shared decision-making. As safety issues often affect potential therapeutic choices, additional consideration was given to relevant comorbidities. These GRAPPA treatment recommendations provide up-to-date, evidence-based guidance on PsA management for clinicians and people with PsA.

Coates LC ，Soriano ER ，Corp N ，Bertheussen H ，Callis Duffin K ，Campanholo CB ，Chau J ，Eder L ，Fernández-Ávila DG ，FitzGerald O ，Garg A ，Gladman DD ，Goel N ，Helliwell PS ，Husni ME ，Jadon DR ，Katz A ，Laheru D ，Latella J ，Leung YY ，Lindsay C ，Lubrano E ，Mazzuoccolo LD ，Mease PJ ，O'Sullivan D ，Ogdie A ，Olsder W ，Palominos PE ，Schick L ，Steinkoenig I ，de Wit M ，van der Windt DA ，Kavanaugh A ，GRAPPA Treatment Recommendations domain subcommittees ... -  《-》

Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.

Gossec L ，Coates LC ，de Wit M ，Kavanaugh A ，Ramiro S ，Mease PJ ，Ritchlin CT ，van der Heijde D ，Smolen JS ... -  《-》